KRAS G12D: How Direct Inhibition Is Advancing Toward Targeted Degradation
KRAS G12D is an important driver mutation in solid tumors such as pancreatic, colorectal, and lung cancers. The emergence of molecules such as MRTX1133 has demonstrated that KRAS G12D can be directly targeted pharmacologically, whereas targeted protein degradation technologies such as PROTACs ...
危险品化学品经营许可证（带存储）